Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders. The company has no approved products as of its FY2025 10-K filed February 26, 2026, and generates no product revenue, relying instead on collaboration agreements and capital markets to fund operations. Its lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for focal onset seizures, primary generalized tonic-clonic seizures, major depressive disorder, and bipolar disorder. The Phase 3 X-TOLE2 study in focal onset seizures completed enrollment with 380 patients randomized, with topline data anticipated in the first half of March 2026. A second Phase 3 study, X-TOLE3, is enrolling internationally to support regulatory submissions outside the United States. Xenon is pursuing both independent commercialization and collaboration pathways for azetukalner. The company is incorporated and operates as Xenon Pharmaceuticals Inc. with its common shares listed on the Nasdaq Global Market.

Revenue model

Pre-commercial stage. No product revenue as of FY2025. Funding comes from collaboration agreements and equity capital markets. Commercial revenue is contingent on regulatory approval of pipeline candidates.

Products and services

Azetukalner: a novel Kv7 potassium channel opener in Phase 3 development for focal onset seizures (X-TOLE2 and X-TOLE3 studies) and primary generalized tonic-clonic seizures, with additional studies in major depressive disorder and bipolar disorder.

Customers and end markets

Target end markets are neurology and neuropsychiatry, specifically epilepsy (focal onset seizures, primary generalized tonic-clonic seizures) and neuropsychiatric disorders (major depressive disorder, bipolar disorder). No commercial customers as of FY2025.

Value-chain role

Drug discovery and clinical-stage development. Xenon originates and advances candidates through clinical trials, with commercialization pursued independently or through collaborators.

Geographic exposure

Primary regulatory target is the United States (FDA). X-TOLE3 is enrolling internationally, including countries outside the United States and Japan, to support ex-U.S. regulatory submissions.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Aurinia Pharmaceuticals Inc Fusion Pharmaceuticals Inc. Repare Therapeutics Inc. Zymeworks BC Inc.